PMID: 7075642Jan 1, 1982Paper

Pharmacokinetics of propranolol and sotalol in hyperthyroidism

European Journal of Clinical Pharmacology
A AroH Sundquist


The elimination and bioavailability of two beta-blocking agents, propranolol and sotalol, were studied in 10 thyrotoxic patients, both before and after treatment with iodine-131. Each subject received in random order propranolol 160 mg and sotalol 160 mg as single oral doses both while hyperthyroid and after euthyroidism had been achieved. The pharmacokinetics of sotalol was not affected by hyperthyroidism, whereas serum propranolol concentrations were significantly lower during hyperthyroidism than in the euthyroid state. During hyperthyroidism, the bioavailability of propranolol was significantly reduced (p less than 0.05) and its clearance was increased (p less than 0.005), whereas there was no difference in its serum t 1/2. This indicates that the bioavailability of propranolol in hyperthyroidism is reduced by a mechanism which may depend on increased first-pass metabolism in the liver, or on an increased distribution volume of the drug. Both propranolol and sotalol caused a slight decrease in serum tri-iodothyronine concentration. As the effects of beta-blocking agents on the symptoms of hyperthyroidism are correlated with the serum concentration of the drugs, sotalol, with its long half-life and unaltered elimination in h...Continue Reading


Feb 1, 1977·British Journal of Clinical Pharmacology·J M BellD G McDevitt
Mar 1, 1979·Clinical Pharmacokinetics·P A Routledge, D G Shand
Dec 1, 1979·British Journal of Clinical Pharmacology·L E MurchisonP D Bewsher
May 1, 1979·Clinical Endocrinology·J FeelyJ Crooks
Oct 1, 1979·British Journal of Clinical Pharmacology·J FeelyI H Stevenson
May 1, 1977·The Journal of Clinical Endocrinology and Metabolism·R P VerhoevenM A Schalekamp
Jun 1, 1977·Clinical Endocrinology·G LottiA Masala
Feb 15, 1979·The New England Journal of Medicine·S RubenfeldP O Kohler
Jan 1, 1976·Clinical Pharmacokinetics·M Eichelbaum
Nov 1, 1976·Clinical Endocrinology·W J Irvine, A D Toft
Feb 3, 1977·The New England Journal of Medicine·M ErikssonP O Kohler
Sep 22, 1977·The New England Journal of Medicine·R HellmanW D Mason
Sep 10, 1977·British Medical Journal·J Feely, T B Counihan
Jul 1, 1976·Acta Pharmacologica Et Toxicologica·M AnttilaH Sundquist
Oct 2, 1975·The New England Journal of Medicine·D J Greenblatt, J Kock-Weser
Jun 1, 1971·Annals of Internal Medicine·W GrossmanL Dexter
Jun 1, 1971·Journal of Pharmaceutical Sciences·E R Garrett, K Schnelle
Nov 1, 1974·Kidney International·S E BradleyP Réville
Sep 1, 1974·Clinical Pharmacology and Therapeutics·H SundquistM Arstila
Jan 1, 1970·Clinical Pharmacology and Therapeutics·D G ShandJ A Oates
Mar 8, 1980·Lancet·J Feely
Nov 8, 1980·British Medical Journal·N D BaxG T Tucker
Jan 1, 1980·British Journal of Clinical Pharmacology·J G RiddellD G McDevitt
Jul 1, 1980·Clinical Pharmacology and Therapeutics·J FeelyJ Crooks
Nov 1, 1980·Clinical Pharmacology and Therapeutics·J G RiddellD G McDevitt

❮ Previous
Next ❯


Jan 1, 1987·European Journal of Clinical Pharmacology·M PokrajacV M Varagić
Jul 1, 1992·The American Journal of Medicine·D L Geffner, J M Hershman
Jun 1, 1982·British Journal of Clinical Pharmacology·N R PedenJ Crooks
Apr 15, 2020·Current Drug Metabolism·Muhammad Nasir KalamNaveed Ahmed

❮ Previous
Next ❯

Related Concepts

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Epigenetics Insights from Twin Studies

Find the latest research on epigenetics and twin studies here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.


Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Regulation of Vocal-Motor Plasticity

Dopaminergic projections to the basal ganglia and nucleus accumbens shape the learning and plasticity of motivated behaviors across species including the regulation of vocal-motor plasticity and performance in songbirds. Discover the latest research on the regulation of vocal-motor plasticity here.

Myocardial Stunning

Myocardial stunning is a mechanical dysfunction that persists after reperfusion of previously ischemic tissue in the absence of irreversible damage including myocardial necrosis. Here is the latest research.